CD8A and gastric cancer: In a gastric cancer xenograft model, treatment with mBYD increased the CD4+/CD8+ T-cell ratio and decreased the proportions of PD-1-expressing CD8+ T cells and regulatory T cells (Tregs), thereby enhancing antitumor immunity.